NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Shares Plunge on Top-line Phase 2 Data of NSI-189 for MDD

Shares of Neuralstem (NASDAQ: CUR) plummeted 57% following the company’s release of top-line data from its exploratory phase 2 clinical trial on the efficacy of NSI-189 for Major Depressive Disorder (MDD). The trial did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS). The trial evaluated NSI-189 at 40 mg once daily and 40 mg twice daily compared to placebo. The 40 mg once daily dose was directionally positive on the MADRS. One of the trial’s two secondary endpoints, the patient-rated Symptoms of Depression Questionnaire (SDQ), achieved statistical significance with the once daily dose in the overall sequential parallel comparison design (SPCD) analysis. “The directionally positive signals across multiple depression scales are encouraging and we look forward to further evaluation of the full dataset in the coming months,” Neuralstem chairman and CEO Rich Daly stated in the news release.

To view the full press release, visit:

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is the lead compound in Neuralstem’s neurogenic small molecule program. NSI-566 is a stem cell therapy being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology. For more information, visit

More from NetworkNewsBreaks

Flex Pharma, Inc.’s (NASDAQ: FLKS) FLX-787 Receives Fast Track Designation from FDA to Treat Severe ALS Cramps

ORHub, Inc. (ORHB) Announces Launch of Neurosurgery Service Line

Eltek (NASDAQ: ELTK) Shares Swell on $3M Order by Governmental Authority

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) is a division of NetworkNewsWire (NNW) focused on providing rapid summaries of corporate news that caught the attention of the NNW team. NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s